Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Feb 14;2(2):CD006771.
doi: 10.1002/14651858.CD006771.pub3.

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism

Lindsay Robertson  1 , James Strachan  2
Affiliations
Meta-Analysis

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism

Lindsay Robertson et al. Cochrane Database Syst Rev. .

Abstract

Background: Venous thromboembolism (VTE) is a prevalent and serious condition. Its medical treatment requires anticoagulation, usually with either unfractionated or low molecular weight heparin (LMWH). Administration of unfractionated heparin (UFH) is usually intravenous (IV) but can be subcutaneous as well. This is an update of a review first published in 2009.

Objectives: To assess the effects of subcutaneous UFH versus intravenous UFH, subcutaneous LMWH or any other anticoagulant drug for the initial treatment of venous thromboembolism.

Search methods: For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched 30 November 2016) and CENTRAL (2016, Issue 10). The Cochrane Vascular Information Specialist also searched trials registries for details of ongoing or unpublished studies.

Selection criteria: Randomised controlled trials comparing subcutaneous UFH to control, such as subcutaneous LMWH, continuous intravenous UFH or other anticoagulant drugs in participants with acute venous thromboembolism.

Data collection and analysis: Two review authors (JS and LR) independently extracted data and assessed the risk of bias in the trials. We used meta-analyses when we considered heterogeneity low. The primary outcomes were symptomatic recurrent venous thromboembolism (deep vein thrombosis and/or pulmonary embolism), VTE-related mortality, adverse effects of treatment including major bleeding, and all-cause mortality. We calculated all outcomes using an odds ratio (OR) with a 95% confidence interval (CI).

Main results: We included one additional study in this update, bringing the total number of studies in the review to 16 randomised controlled trials, with a total of 3593 participants (1745 participants in the intervention group and 1848 participants in the control group). Eight trials used intravenous UFH as the control treatment, seven trials used LMWH, and one trial had three arms with both drugs as the controls. We did not identify trials comparing subcutaneous UFH with other anticoagulant drugs. We downgraded the quality of the evidence to low due to lack of blinding in studies, which led to a risk of performance bias, and also for imprecision, as reflected by the wide confidence intervals.When comparing subcutaneous versus IV UFH, there was no difference in the incidence of symptomatic recurrent VTE at three months (odds ratio (OR) 1.66, 95% confidence interval (CI) 0.89 to 3.10; 8 studies; N = 965; low-quality evidence), symptomatic recurrent deep vein thrombosis (DVT) at three months (OR 3.29, 95% CI 0.64 to 17.06; 1 study; N = 115; low-quality evidence), pulmonary embolism (PE) at three months (OR 1.44, 95% CI 0.73 to 2.84; 9 studies; N = 1161; low-quality evidence), VTE-related mortality at three months (OR 0.98, 95% CI 0.20 to 4.88; 9 studies; N = 1168; low-quality evidence), major bleeding (OR 0.91, 95% CI 0.42 to 1.97; 4 studies; N = 583; low-quality evidence) or all-cause mortality (OR 1.74, 95% CI 0.67 to 4.51; 8 studies; N = 972; low-quality evidence). There were no episodes of asymptomatic VTE occurring within three months of the commencement of treatment.When comparing subcutaneous UFH versus LMWH, there was no difference in the incidence of recurrent VTE at three months (OR 1.01, 95% CI 0.63 to 1.63; 5 studies; N = 2156; low-quality evidence), recurrent DVT at three months (OR 1.38, 95% CI 0.73 to 2.63; 3 studies; N = 1566; low-quality evidence), PE (OR 0.84, 95% CI 0.36 to 1.96; 5 studies, N = 1819; low-quality evidence), VTE-related mortality (OR 0.53, 95% CI 0.17 to 1.67; 8 studies; N = 2469; low-quality evidence), major bleeding (OR 0.72, 95% CI 0.43 to 1.20; 5 studies; N = 2300; low-quality evidence) or all-cause mortality (OR 0.73, 95% CI 0.50 to 1.07; 7 studies; N = 2272; low-quality evidence). There were no episodes of asymptomatic VTE occurring within three months of the commencement of treatment.

Authors' conclusions: There is no evidence of a difference between subcutaneous versus intravenous UFH for preventing VTE recurrence, VTE-related or all-cause mortality, and major bleeding. According to GRADE criteria, the quality of the evidence was low. There is also no evidence of a difference between subcutaneous UFH and LMWH for preventing VTE recurrence, VTE-related or all-cause mortality or major bleeding.

PubMed Disclaimer

Conflict of interest statement

JS: none known. LR: none known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 1 Symptomatic recurrent VTE at 3 months.
1.2
1.2. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 2 Symptomatic recurrent DVT at 3 months.
1.3
1.3. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 3 PE at 3 months.
1.4
1.4. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 4 VTE‐related mortality at 3 months.
1.5
1.5. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 5 Major bleeding.
1.6
1.6. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 6 All‐cause mortality.
1.7
1.7. Analysis
Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin, Outcome 7 Treatment related morbidity ‐ minor bleeding.
2.1
2.1. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 1 Symptomatic recurrent VTE at 3 months.
2.2
2.2. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 2 Symptomatic recurrent DVT at 3 months.
2.3
2.3. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 3 PE at 3 months.
2.4
2.4. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 4 VTE‐related mortality at 3 months.
2.5
2.5. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 5 Major bleeding.
2.6
2.6. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 6 All‐cause mortality.
2.7
2.7. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 7 Treatment related morbidity ‐ minor bleeding.
2.8
2.8. Analysis
Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin, Outcome 8 Treatment related morbidity ‐ HIT.
3.1
3.1. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 1 Symptomatic recurrent VTE at 3 months.
3.2
3.2. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 2 Symptomatic recurrent DVT at 3 months.
3.3
3.3. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 3 PE at 3 months.
3.4
3.4. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 4 VTE‐related mortality at 3 months.
3.5
3.5. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 5 Major bleeding.
3.6
3.6. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 6 All‐cause mortality.
3.7
3.7. Analysis
Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies), Outcome 7 Treatment‐related morbidity.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Andersson 1982 {published data only}
    1. Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, et al. Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep‐vein thrombosis. Thrombosis Research 1982;27(6):631‐9. - PubMed
Belcaro 1999 {published data only}
    1. Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, Sanctis MT, Incandela L, et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology 1999;50(10):781‐7. - PubMed
Bentley 1980 {published data only}
    1. Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. Thrombosis Research 1980;18(1‐2):177‐87. - PubMed
Doyle 1987 {published data only}
    1. Doyle DJ, Turpie AG, Hirsh J, Best C, Kinch D, Levine MN, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Annals of Internal Medicine 1987;107(4):441‐5. - PubMed
Faivre 1987 {published data only}
    1. Faivre R, Neuhart E, Kieffer Y, Bassand JP, Maurat JP. Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study [Efficacité d'un fragment d'héparine de très faible poids moléculaire (CY 222) comparée a l'héparine standard chez des patients porteurs d'une thrombose veineuse profonde. Étude randomisée]. Journal des Maladies Vasculaires 1987;12(Suppl. B):145‐6. - PubMed
    1. Faivre R, Neuhart Y, Kieffer Y, Apfe lF, Magnin D, Didier D, et al. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'héparine de bas poids ,olecuaire. Étude randomisée]. Presse Medicale 1988;17(5):197‐200. - PubMed
Holm 1986 {published data only}
    1. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. European Journal of Clinical Pharmacology 1990;39(2):107‐12. - PubMed
    1. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16(Suppl. 2):30‐7. - PubMed
Hull 1986 {published data only}
    1. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal‐vein thrombosis. New England Journal of Medicine 1986;315(18):1109‐14. - PubMed
Kearon 2006 {published data only}
    1. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, et al. Comparison of fixed‐dose weight‐adjusted unfractionated heparin and low‐molecular‐weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296(8):935. - PubMed
Krähenbühl 1979 {published data only}
    1. Krähenbühl B, Simon CA, Bouvier CA, Schinas P, Hopf MA, Cochet B. Heparin treatment. Comparison between intravenous and subcutaneous administration. Schweizerische Medizinische Wochenschrift 1979;109(36):1322‐5. - PubMed
Leizorovicz 2011 {published data only}
    1. Leizorovicz A. IRIS an ongoing, international, multicentre, open, centrally randomised, parallel group study with tinzaparin or unfractionated heparin (ufh) administered subcutaneously (sc) to patients with deep vein thrombosis (DVT) or pulmonary embolism (PE). XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6‐12; Geneva 2007:Abstract no: P‐M‐673.
    1. Leizorovicz A. Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency‐the IRIS Trial [Abstract No. 434]. Blood 2009;112:166.
    1. Leizorovicz A, Siguret V, Mottier D. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research 2011;128(1):27‐34. - PubMed
    1. NCT00277394. Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis [Safety profile of Innohep versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis]. clinicaltrials.gov/ct2/show/NCT00277394 (date first received 13 January 2006).
    1. Siguret V, Deudon C, Golmard J, Leizorovicz A, Pautas E, Gouin‐Thibault I. Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis 2013;11(Suppl 2):805.
Lopaciuk 1990 {published data only}
    1. Lopaciuk S, Misiak A, Wisawski S, Ciesielski L, Korzycki J, Judkiewicz L, et al. Subcutaneous injections and intravenous infusion of sodium salt of heparin in the treatment of thrombosis of deep veins of the lower extremities [Podskórne wstrzyknięcia i dożylny wlew soli sodowej heparyny w leczeniu zakrzepicy żył głębokich kończyn dolnych]. Polski Tygodnik Lekarski 1990;45(47‐48):949‐52. - PubMed
Lopaciuk 1992 {published data only}
    1. Lopaciuk S, Meissner AJ, Filipeckil S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis 1992;68(1):14‐8. - PubMed
Peternel 2002 {published data only}
    1. Peternel P, Terbizan M, Tratar G, Bozic M, Horvat D, Salobir B, et al. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low‐molecular weight heparin. Thrombosis Research 2002;105(3):241‐6. - PubMed
Pini 1990 {published data only}
    1. Pini M, Pattachini C, Quintavalla R, Poli T, Megha A, Tagliaferri A, et al. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis? a randomized clinical trial. Thrombosis and Haemostasis 1990;64(2):222‐6. - PubMed
Prandoni 2004 {published data only}
    1. Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine 2004;164(10):1077‐83. - PubMed
Walker 1987 {published data only}
    1. Walker MG, Shaw JW, Cumming JGR, Lea Thomas M. Subcutaneous calcium heparin versus intravenous sodium heparin in the treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. BMJ 1987;294(6581):1189‐92. - PMC - PubMed

References to studies excluded from this review

Fagher 1981 {published data only}
    1. Fagher B, Lundh B. Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. Acta Medica Scandinavica 1981;210(5):357‐61. - PubMed
Glazier 1976 {published data only}
    1. Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236(12):1365‐7. - PubMed
Gruber 1979 {published data only}
    1. Gruber UF, Brun M, Brunner R, Gaugler U, Müller J, Schumacher S, et al. Subcutaneous heparin or intravenous dextran? [S.c. Heparin oder i.v. Dextran?]. Helvetica Chirurgica Acta 1979;46(1‐2):65‐8. - PubMed
Horbach 1996 {published data only}
    1. Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, et al. A fixed‐dose combination of low molecular weight heparin with dihydroergotamine versus adjusted‐dose unfractionated heparin in the prevention of deep‐vein thrombosis after total hip replacement. Thrombosis and Haemostasis 1996;75(2):246‐50. - PubMed
Lockner 1986 {published data only}
    1. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986;16(Suppl. 2):25‐9. - PubMed
Marchiori 2002 {published data only}
    1. Marchiori A, Verlato F, Sabbion P, Camporese G, Rosso F, Mosena L, et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica 2002;87(5):523‐7. - PubMed
Monreal 1994 {published data only}
    1. Monreal M, Lafoz E, Olive A, Rio LD, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis 1994;71(1):7‐11. - PubMed
Nakamura 2010 {published data only}
    1. Nakamura M, Okano Y, Minamigichi H, Tsujimoto H, Nakajima H, Kunieda T. Clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Chest 2010;138(4 MeetingAbstracts):410A. - PubMed
NCT01956955 {published data only}
    1. NCT01956955. Comparison of low‐molecular‐weight heparin (LMWH) and unfractionated heparin (UFH) in combination with thrombolytic treatment of acute massive pulmonary thromboembolism. clinicaltrials.gov/ct2/show/NCT01956955 (Date first received 27 September 2013).
Quiros 2001 {published data only}
    1. Quiros M. Use of heparin of low molecular weight in the ambulatory handling of patients with deep venous thrombosis. Comparative study: heparin non‐divided versus low molecular weight heparin [Uso de heparinas de bajo peso molecular en el manejo ambulatorio de pacientes con trombosis venosa profunda. Estudio comparativo: heparina no fraccionada vs heparina de bajo peso molecular]. Revista Costarricense de Cardiologia 2001;3(2):8‐13.
Riess 2014 {published data only}
    1. Riess H, Becker LK, Melzer N, Harenberg J. Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. Blood Coagulation & Fibrinolysis 2014;25(8):838‐44. - PubMed
Rodgers 1999 {published data only}
    1. Rodgers GM. Treatment of cancer‐associated deep‐vein thrombosis with enoxaparin: comparison with unfractionated heparin therapy. Proceedings of the American Society of Clinical Oncology 1999; Vol. 18:193a.
Romera 2009 {published data only}
    1. Romera A, Cairols MA, Vila‐Coll R, Marti X, Colome E, Bonell A, et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery 2009;37(3):349‐56. - PubMed
Ucar 2015 {published data only}
    1. Ucar EY, Akgun M, Araz O, Tas H, Kerget B, Meral M, et al. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment: randomized controlled parallel group study. Lung 2015; Vol. 193, issue 1:121‐7. - PubMed
Van Doormaal 2009 {published data only}
    1. Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis 2009;101(4):762‐9. - PubMed
Van Doormaal 2010 {published data only}
    1. Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M, et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis 2010;104(1):86‐91. - PubMed

Additional references

Anderson 2003
    1. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 Suppl 1):1‐9. - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. - PMC - PubMed
Chengelis 1996
    1. Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery 1996;24(5):745‐9. - PubMed
Cushman 2007
    1. Cushman M. Epidemiology and risk factors for venous thrombosis. Seminars in Hematology 2007;44(2):62‐9. - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Dolovich 2000
    1. Dolovich LR, Ginsberg JS Douketis JD, Holbrook AM, Cheah G. A meta‐analysis comparing low‐molecular‐weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Archives of Internal Medicine 2000;160(2):181‐8. - PubMed
Erkens 2010
    1. Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD001100.pub3] - DOI - PubMed
Gould 1999
    1. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low‐molecular‐weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta‐analysis of randomized controlled trials. Annals of Internal Medicine 1999;130(10):800‐9. - PubMed
GRADEpro GDT [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 2 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Heit 2015
    1. Heit JA. Epidemiology of venous thromboembolism. Nature Reviews Cardiology 2015;12(8):464‐74. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hommes 1992
    1. Hommes DW, Bura A, Mazzolai L, Büller HR, Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta‐analysis. Annals of Internal Medicine 1992;116(4):279‐84. - PubMed
Kearon 2012
    1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest 2012;142(6):1698‐704. - PMC - PubMed
McLean 1916
    1. McLean J. The thromboplastic action of cephalin. American Journal of Physiology 1916;41:250‐7.
Munro 2008
    1. Munro A, English C. Subcutaneous heparin is as good as low‐molecular weight heparin in the acute treatment of thromboembolic disease. Emergency Medicine Journal 2008;25(5):287‐9. - PubMed
Nasr 2015
    1. Nasr H, Scriven JM. Superficial thrombophlebitis (superficial venous thrombosis). BMJ 2015;350:h2039. - PubMed
NICE 2010
    1. National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reduc... (accessed 30 September 2015).
Quinlan 2004
    1. Quinlan DJ, McQuillan A, Eikelboom JW. Low‐molecular‐weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta‐analysis of randomized, controlled trials. Annals of Internal Medicine 2004;140(3):175‐83. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schulman 2005
    1. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. Journal of Thrombosis and Haemostasis 2005;3(4):692‐4. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
White 2003
    1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I‐4‐I‐8. - PubMed

References to other published versions of this review

Vardi 2007
    1. Vardi M, Bitterman H. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006771] - DOI - PubMed
Vardi 2009
    1. Vardi M, Zittan E, Bitterman H. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006771.pub2] - DOI - PubMed

Publication types

MeSH terms